FDA plans pilot for third party review
This article was originally published in Clinica
Executive Summary
A pilot programme for third party review of selected 510(k) notifications is expected by the US FDA to get under way early in fiscal 1996. Part of the agency's policy reform package announced in April (see Clinica No 649, p 6), the pilot project will be restricted to third party review - but not clearance - of low-risk medical devices.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.